34 results about "Fatty Acid Synthases" patented technology

The present invention relates to proteins involved in fatty acid synthesis, such as fatty acid synthases (FAS) variants, comprising one or more polypeptide chains, wherein said polypeptide chain(s) comprise one or more subunits comprising a malonyl / palmitoyl transferase domain (MPT domain), acetyl transferase domain (AT domain), and ketoacyl synthase domain (KS domain), and at least one amino acid substitution in the MPT domain at a position corresponding to R130, in the AT domain at a position corresponding to I306, and / or in the KS domain, preferably in the acyl binding channel and / or at KS domain binding site to ACP, to modulate affinities of acyl intermediates, and optionally further amino acid substitution(s). The present invention relates to the respective polypeptide domains. The present invention further relates to nucleic acid molecules encoding the proteins (or the polypeptide domains) and to host cells containing said nucleic acid molecules. The present invention further relates to a method for the production of short fatty acids, CoA esters of short fatty acids, ethyl esters of short fatty acids, esters of short fatty acids with other metabolites, and / or enzyme bound short fatty acids (C6 to C12), comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention further relates to a method for the production of biofuels, flavoring compounds and / or fine chemicals, comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention also relates to the use of the proteins, nucleic acids molecule or host cells for the bulk production of short fatty acids (C6 to C12), the specific production of C6 fatty acids and / or C8 fatty acids, the bulk production of CoA esters of short fatty acids (C6 to C12), the specific production of C6-CoA esters and / or C8-CoA esters, the bulk production of ethyl esters of short fatty acids (C6 to C12), the specific production of C6 fatty acid ethyl esters and / or C8 fatty acid ethyl esters, the bulk production of esters of short fatty acids (C6 to C12) with other metabolites, the specific production of C6 fatty acid esters with other metabolites and / or C8 fatty acid esters with other metabolites, the bulk production of enzyme bound short fatty acids (C6 to C12), the specific production of enzyme bound C6 fatty acids and / or enzyme bound C8 fatty acids, the production of biofuels, fine chemicals and / or flavoring substances.

The present disclosure generally relates to novel compounds as a fatty acid synthase inhibitor useful for the treatment of infection diseases, cancers, or metabolic diseases that malfunction of fatty acid synthase is involved. In particular this present invention directs to malonyl-coenzyme A (CoA) mimetics and methods of use thereof. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using compounds disclosed herein.

The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.

Compounds of formula (I), wherein R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase and are especially useful in the treatment of diseases such as cancer , cardiovascular disease, central nervous system injury and different forms of inflammation.

The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob / Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob / Lepob mice. Full-length ENHO1 peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and / or energy imbalance.

The invention discloses a fatty acid synthase inhibitor, its production method and application, and its purpose is to provide a fatty acid synthase inhibitor, its production method and its prevention and adjuvant treatment of related diseases with fatty acid synthase as the target in the application. The fatty acid synthase inhibitor is obtained by treating tea warm extract or catechin compounds with acid. The preparation method of the fatty acid synthase inhibitor provided by the invention is to react the warm tea extract or catechin compounds with acid at 25-120°C to obtain the fatty acid synthase inhibitor. The present invention has significant potential applications in the prevention and auxiliary treatment of diseases targeted at fatty acid synthase, especially in the medicines and health products for weight control, prevention and auxiliary treatment of obesity-related diseases, and prevention and auxiliary treatment of cancer value.